Evolocumab Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
Latest Information Update: 18 Nov 2020
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Amgen
- 13 Nov 2020 Status changed from recruiting to discontinued.
- 19 Dec 2017 Planned End Date changed from 29 Apr 2032 to 28 Apr 2032.
- 19 Dec 2017 Planned primary completion date changed from 29 Apr 2032 to 28 Apr 2032.